SHS sells EIT to Johnson & Johnson

The sale ends a two-year holding period for SHS, which acquired the company with capital from SHS IV Fonds, a €125m vehicle focused on life sciences and medical technology.

Johnson & Johnson said it will use its global commercial infrastructure to make EIT's technology available to patients around the world.

The acquisition of EIT will allow DePuy Synthes (the orthopaedics business of Johnson & Johnson) to enhance its interbody implant portfolio.

Previous funding
SHS acquired a 35% stake in EIT in 2016. The funding was used for product development and international expansion.

Company
Founded in 2014 and based in Tuttlingen, EIT produces bio-compatible titanium spine implants using a 3D printer.

People
SHS Gesellschaft für Beteiligungsmanagement – Bernhard Schirmers (managing partner).
Emerging Implant Technologies – Guntmar Eisen (founder, managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• Germany
• Trade sale